- tags:ASCRS
Business
ASOA names ASCRS leader as new executive director
Current ASCRS Foundation Executive Director Abigail Markward is taking the helm.
Events
ASCRS launches AT IOL-focused educational initiative
Exclusive two-day Business of Refractive Cataract Surgery Summit kicks off in September for cataract and refractive surgeons and staffers.
Research
First-of-its-kind robotic cataract procedure makes debut at ASCRS
David F. Chang, MD, presents on ForSight Robotics’ first-of-its-kind hybrid intraocular robotic ophthalmic platform.
Business
ASCRS names Vance Thompson, MD, as president
Internationally-recognized specialist in laser vision correction and advanced cataract surgery will be inducted during the 2024 annual meeting.
Events
Canadian ophthalmologist receives 2024 ASCRS Foundation Chang-Crandall Humanitarian Award
Martin Spencer, MD, brings nearly 40 decades of humanitarian work.
Business
ASCRS names new executive director
Ophthalmic industry veteran Abigail Markward will lead the ASCRS Foundation.
Research
Orbis and FundamentalVR roll out VR cataract surgery training
Immersive simulation is designed exclusively to train surgeons in low- and middle-income countries.
Research
SAHARA crossover trial reports significant continued advantages of TearCare for DED
Additional 6-month data supports Sights Sciences’ tech vs Restasis as a primary treatment for addressing the underlying root cause of MGD.
Products
RxSight launches newest Light Adjustable Lens
The LAL+ marks the next installment of the first and only customizable IOL for cataract surgery.
Research
Keratoconus eye drop regenerates lost collagen in the eye
TheiaNova’s world-first therapy of its kind is featured during ASCRS’s Winning Pitch Challenge as part of the Eyecelerator conference.
Products
Johnson & Johnson unveils TECNIS Odyssey presbyopia-correcting IOL
Real-world data presented during ASCRS reports the IOL demonstrates a full range of continuous vision.
Research
Sight Sciences reports new data from GEMINI extension trial on OMNI Surgical System
Findings build on original 12-month results supporting its efficacy in lowering IOP and medication adherence in OAG.
Products